Clinical study of Arogyavardhini compound and lifestyle modification in management of metabolic syndrome: A double‑blind placebo controlled randomized clinical trial.

Ayu Pub Date : 2019-07-01 Epub Date: 2020-08-08 DOI:10.4103/ayu.AYU_79_19
Bharatkumar Chhaganbhai Padhar, Alankruta R Dave, Mandip Goyal
{"title":"Clinical study of <i>Arogyavardhini</i> compound and lifestyle modification in management of metabolic syndrome: A double‑blind placebo controlled randomized clinical trial.","authors":"Bharatkumar Chhaganbhai Padhar,&nbsp;Alankruta R Dave,&nbsp;Mandip Goyal","doi":"10.4103/ayu.AYU_79_19","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome (MS) is a cluster of obesity, hypertriglyceridemia, impaired glucose tolerance, and insulin resistance. The sedentary lifestyle settles on the phenotypical expression of a genetically acquired trait in an obese person. Weight control and a healthy lifestyle remain primary and effective strategies for prevention and management of the MS. The lifestyle modifications mentioned for <i>Santarpanjanya</i> (disorders due to over nutrition) diseases and <i>Arogyavardhini</i> compound that can improve metabolism and reduce weight were selected for a present clinical trial to assess and compare their efficacy in the management of the MS.</p><p><strong>Materials and methods: </strong>Seventy‑five patients were registered for the trial and randomly divided into two groups. Patients were treated with lifestyle modification with and without <i>Arogyavardhini</i> compound for 8 weeks.</p><p><strong>Results: </strong>Thirty‑five patients in each group could complete the course of treatment. Lifestyle modification alone and with <i>Arogyavardhini</i> compound resulted in 1.32% and 3.06% decrease in waist circumference, 5.81% and 18.03% decrease in serum triglycerides, 4.43% and 6.89% decrease in systolic blood pressure, 3.82% increase and 2.48% decrease in fasting blood sugar, 9.13% and 5.56% increase in high‑density lipoprotein, respectively. The decrease in waist circumference, systolic blood pressure was statistically significant in the both groups.</p><p><strong>Conclusion: </strong><i>Arogyavardhini</i> compound, along with lifestyle modification was found more effective than lifestyle modification alone in the management of MS.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"40 3","pages":"171-178"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/78/AYU-40-171.PMC7685257.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ayu","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ayu.AYU_79_19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/8/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Background: Metabolic syndrome (MS) is a cluster of obesity, hypertriglyceridemia, impaired glucose tolerance, and insulin resistance. The sedentary lifestyle settles on the phenotypical expression of a genetically acquired trait in an obese person. Weight control and a healthy lifestyle remain primary and effective strategies for prevention and management of the MS. The lifestyle modifications mentioned for Santarpanjanya (disorders due to over nutrition) diseases and Arogyavardhini compound that can improve metabolism and reduce weight were selected for a present clinical trial to assess and compare their efficacy in the management of the MS.

Materials and methods: Seventy‑five patients were registered for the trial and randomly divided into two groups. Patients were treated with lifestyle modification with and without Arogyavardhini compound for 8 weeks.

Results: Thirty‑five patients in each group could complete the course of treatment. Lifestyle modification alone and with Arogyavardhini compound resulted in 1.32% and 3.06% decrease in waist circumference, 5.81% and 18.03% decrease in serum triglycerides, 4.43% and 6.89% decrease in systolic blood pressure, 3.82% increase and 2.48% decrease in fasting blood sugar, 9.13% and 5.56% increase in high‑density lipoprotein, respectively. The decrease in waist circumference, systolic blood pressure was statistically significant in the both groups.

Conclusion: Arogyavardhini compound, along with lifestyle modification was found more effective than lifestyle modification alone in the management of MS.

Abstract Image

Arogyavardhini和生活方式改变治疗代谢综合征的临床研究:一项双盲安慰剂对照随机临床试验
背景:代谢综合征(MS)是一组肥胖、高甘油三酯血症、糖耐量受损和胰岛素抵抗。久坐不动的生活方式决定了肥胖者基因获得性特征的表型表达。控制体重和健康的生活方式仍然是预防和管理多发性硬化症的主要和有效的策略。本临床试验选择了Santarpanjanya(由于营养过度引起的失调)疾病的生活方式改变和Arogyavardhini化合物,以评估和比较它们在多发性硬化症管理中的疗效。75名患者登记参加试验,并随机分为两组。患者分别接受8周的生活方式改变治疗,其中包括Arogyavardhini化合物。结果:每组35例患者均能完成疗程。生活方式改变组和Arogyavardhini组腰围分别下降1.32%和3.06%,血清甘油三酯分别下降5.81%和18.03%,收缩压分别下降4.43%和6.89%,空腹血糖分别升高3.82%和2.48%,高密度脂蛋白分别升高9.13%和5.56%。两组患者的腰围、收缩压下降均有统计学意义。结论:复方Arogyavardhini联合生活方式改变治疗MS比单独改变生活方式更有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ayu
Ayu
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信